Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Glaucoma
Phase Not Applicable
Enrollment 200
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimeter and the Humphrey Field Analyzer (HFA) perimeter will be used to assess retinal functionality; an Optical Coherence Tomography (OCT) examination will also be performed to evaluate and obtain clinical information about the structure of the retina.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Equivalence between Compass and HFA in terms of estimation of the global progression rate (MD progression slope). (1 visit every 4 months (10 visits total), up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-05-06
Completion: 2028-11-06
Eligibility
Age: 40 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centervue SpA
Principal Investigators:
  • Luca M. Rossetti, Prof. (PRINCIPAL_INVESTIGATOR) - Clinica oculistica Ospedale San Paolo
Contact Information
Study Contact:
Chiara Rui
+39 049 501 8399
chiara.rui@icare-world.com
Luca M Rossetti, Prof.
02/81844556
luca.rossetti@unimi.it
Clinica oculistica Ospedale San Paolo
Luca M. Rossetti, Prof.
Clinica oculistica Ospedale San Paolo
Interventions
N/A
Study Locations (2 sites)
Clinica oculistica Ospedale San Paolo, Milan, Milano 20142 Italy
Glaucoma Research Center, IRCCS Fondazione "G.B. Bietti", Roma, Roma 00184 Italy
Eligibility Criteria
Inclusion Criteria: * Glaucomatous optic nerve head in both eyes; * Age between 40 and 90 years; * Best Corrected Visual Acuity ≤ 0.3 \[logMar\]; * Spherical refraction between -6D and +6D; * Astigmatism between -2D and +2D. Exclusion Criteria: * Any ocular surgery, except for: uncomplicated cataract surgery and/or glaucoma surgery in both eyes performed within 6 months before enrollment; * Any ocular pathology that can affect visual field other than glaucoma; * Use of any drug that can interfere with the correct execution of perimetry or that would produce visual field loss; * Inability to obtain reliable perimetric examinations; * Patients with advanced glaucoma for whom, according to the clinician, a 24-2 grid is not advisable to correctly monitor the patient.
Conditions Stroke, Acute, Stroke, Ischemic
Phase PHASE3
Enrollment 358
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

PRESSURE is a multicenter, prospective, randomized, open, blinded end-point assessed (PROBE) trial, that aims to evaluate the efficacy and safety of drug-induced hypertension using peripheral dilute norepinephrine, in patients with acute ischemic stroke in a perforating artery territory and experiencing early neurological deterioration.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Peripheral intravenous norepinephrine — Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.

Primary Outcomes

  • modified Rankin Scale (mRS) (Day 0)
  • modified Rankin Scale (mRS) (Day 90)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-11-28
Completion: 2027-11-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 358 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Bordeaux
Principal Investigators:
  • Pauline RENOU (STUDY_CHAIR) - University Hospital, Bordeaux
Contact Information
Study Contact:
Pauline RENOU
05-56-79-55-20
pauline.renou@chu-bordeaux.fr
Pauline RENOU
CHU de Bordeaux
Pauline RENOU
CHU de Bordeaux
Interventions
  • Drug: Peripheral intravenous norepinephrine — Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
Study Locations (1 sites)
CHU de Bordeaux, Bordeaux, France
Eligibility Criteria
Inclusion Criteria: * Acute ischemic stroke \< 72 h in a perforating artery territory on brain MRI * Early neurological deterioration or fluctuation, attested by the neurologist in charge, defined by a ≥ 3-point increase in global NIHSS score OR a 2-point increase on motor or ataxia score, whether this deterioration is transient or permanent. * Time between early neurological deterioration and randomization \< 6 hours * Age ≥ 18 years * Contraception required in women of childbearing potential (Intra-uterine device, hormonal contraception associated with inhibition of ovulation (combined or progestogen-only; oral, intravaginal or transdermal), Female Sterilization, Vasectomised partner, sexual abstinence) * Beneficiary of a health insurance system Exclusion Criteria: * \- Pre-Stroke Modified Rankin Score \> 3 * Contraindication to brain Magnetic Resonance Imaging (MRI) * High risk of intracerebral hemorrhage: * Cerebral microbleeds ≥ 10 * Non traumatic focal superficial siderosis * Hemorrhagic transformation of the present ischemic stroke * Previous history of intracerebral hemorrhage (symptomatic or asymptomatic identified on brain MRI) * Intracranial vascular malformation or tumor with suspected risk of rupture or bleeding * Prior intravenous thrombolysis \< 24 hours * Requirement for anticoagulation in the first 7 days after randomization * Systolic blood pressure (SBP) \> 180mmHG and/or mean arterial pressure (MAP) ≥ 110mmHG at inclusion * Large artery atherosclerosis (ipsilateral atherosclerotic stenosis \> 50%), intra and extracranial dissection, or cardio-embolic stroke mechanisms * Drugs with important interactions with norepinephrine: monoamine oxidase inhibitors (including reversible, non-selective agents such as linezolid), tricyclic antidepressants, entacapone. * Pregnancy or breastfeeding
Conditions Glaucoma
Phase NA
Enrollment 192
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is a common and irreversible disease of the optic nerve. It is the second leading cause of blindness worldwide. Glaucoma can be treated with medication, laser therapy, or surgery; the latter is often necessary. Traditional surgeries are invasive and carry a high rate of complications (hypotony, endophthalmitis, cataracts, etc.). Consequently, several types of micro-invasive surgeries (MIGS) and less invasive but effective surgeries, LIGS, have been developed to reduce surgical risks while maintaining effectiveness in lowering intraocular pressure (IOP). PRESERFLO is a drainage system less than 1 mm thick that regulates the outflow of aqueous humor from the eye. It is made of a soft, flexible biomaterial that conforms to the curvature of the eye. This biomaterial does not trigger a negative immune response. PRESERFLO is an example of a recently developed, powerful LIGS procedure (with preliminary results demonstrating efficacy and safety). PRESERFLO is already in use in France (marketing authorization and CE marking obtained) and is covered by social security. This technique is highly effective in lowering IOP, but it may be associated with hypotony, although less frequently than with trabeculectomy. The use of a releasable suture placed inside the Preserflo to limit drainage and, consequently, reduce the risk of hypotony has been described with good results in preliminary studies. Nevertheless, it is necessary to evaluate the efficacy and safety of this technical modification in a randomized, prospective clinical trial to better understand whether this modification is beneficial for improving the treatment of patients with glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Procedure: Classical surgery — After peritomy, coagulation, and the application of 0.04% mitomycin C (as in a trabeculectomy or any filtration surgery), a scleral tunnel is created 3 mm from the limbus using a 1-mm scalpel designed for this purpose, followed by a 25G needle, which is inserted into the eye parallel to the iris. Next, the Preserflo is inserted into this tunnel, away from the cornea and the iris. The outflow of aqueous humor through the Preserflo is tested by injecting BSS into the anterior chamber. The peritomy is then closed (as in a trabeculectomy).
  • Procedure: Intraluminal suture — A 9-0 Ethilon suture is inserted into the distal end of the Preserflo to partially occlude the outflow of aqueous humor through this drain, thereby reducing the risk of postoperative hypotony. The other end of this suture is attached to the cornea, forming a loop (which will allow it to be removed later). Next, the Preserflo and the suture are covered with the Tenon's capsule and the conjunctiva, as in the standard technique.

Primary Outcomes

  • Postoperative hypotonia (12 months after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-17
Completion: 2029-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 192 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hôpital Privé de la Baie
Principal Investigators:
  • Ana Miguel, MD (PRINCIPAL_INVESTIGATOR) - Hôpital Privé de la Baie
Contact Information
Study Contact:
Marion Mandon, PhD
+33 6 78 27 76 72
mmandon@vivalto-sante.com
Marion Mandon, PhD
+33678277672
drc@vivalto-sante.com
Hôpital Privé de la Baie
Interventions
  • Procedure: Classical surgery — After peritomy, coagulation, and the application of 0.04% mitomycin C (as in a trabeculectomy or any filtration surgery), a scleral tunnel is created 3 mm from the limbus using a 1-mm scalpel designed for this purpose, followed by a 25G needle, which is inserted into the eye parallel to the iris. Next, the Preserflo is inserted into this tunnel, away from the cornea and the iris. The outflow of aqueous humor through the Preserflo is tested by injecting BSS into the anterior chamber. The peritomy is then closed (as in a trabeculectomy).
  • Procedure: Intraluminal suture — A 9-0 Ethilon suture is inserted into the distal end of the Preserflo to partially occlude the outflow of aqueous humor through this drain, thereby reducing the risk of postoperative hypotony. The other end of this suture is attached to the cornea, forming a loop (which will allow it to be removed later). Next, the Preserflo and the suture are covered with the Tenon's capsule and the conjunctiva, as in the standard technique.
Study Locations (1 sites)
Hôpital Privé de la Baie, Avranches, 50300 France
Eligibility Criteria
Inclusion Criteria: * Primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma with an indication for glaucoma surgery (defined as uncontrolled intraocular pressure or worsening of visual fields, despite maximum tolerated medical therapy) and an open iridocorneal angle (trabeculum visible on gonioscopy, Shaffer classification grade 3-4) * Healthy, mobile conjunctiva (without scarring or adhesions). * The indication for glaucoma surgery is defined as uncontrolled IOP or worsening of visual fields despite maximum tolerated medical therapy, and with either a previous failure of trabeculectomy or a risk of failure. * Maximum tolerated medical therapy: 3 or more classes of ocular hypotensive treatment, or fewer if there is an allergy or intolerance to the treatment. Visual field defects must be more severe than -3 dB in mean deviation. Exclusion Criteria: * severe systemic pathologies * other ophtalmic pathologies (except cataract) * previous intraocular surgery (except cataract) * neovascular glaucoma or iris neovascularization * pachymetry \< 490µm or \> 620µm * contraindication to PRESERFLO Microshunt
Conditions Breast Cancer, Breast Neoplasms, Breast ...
Phase Not Applicable
Enrollment 800
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to understand why different people have different risks and outcomes for breast cancer and non-breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Biospecimen Collection — Blood collection at baseline and time of surgery
  • Diagnostic Test: Surgical Tissue Collection — Tissue collection will be attempted at time of surgery
  • Behavioral: Survey Collection — Survey collection at baseline, post-surgery, at 1, 3 and 5 year follow up visits

Primary Outcomes

  • Clinical characteristic of participants (survey) (Up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-13
Completion: 2030-01-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Neha Goel, MD, MPH (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Neha Goel, MD, MPH
646-888-4731
goeln1@mskcc.org
George Plitas, MD
646-888-5368
plitasg@mskcc.org
Steven Cole, PhD
(310) 267-4243
University of California, Los Angeles (Specimen Analysis only)
Interventions
  • Other: Biospecimen Collection — Blood collection at baseline and time of surgery
  • Diagnostic Test: Surgical Tissue Collection — Tissue collection will be attempted at time of surgery
  • Behavioral: Survey Collection — Survey collection at baseline, post-surgery, at 1, 3 and 5 year follow up visits
Study Locations (3 sites)
University of California, Los Angeles (Specimen Analysis only), Los Angeles, California 90095 United States
University of Miami (Data Collection Only), Miami, Florida 33136 United States
Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Patients with BIRADS 0-5, seen in breast radiology clinic at University of Miami (UM), Sylvester Comprehensive Cancer Center (SCCC), Jackson Health Systems (JHS) for biopsy. * Any new breast patient seen at UM/SCCC or JHS will be invited to participate in the study. * Men and women 18 years of age and older are eligible to participate in the study. Exclusion Criteria: * Patients who are less than 18 years of age will be considered ineligible. * Patients unable to complete the survey.
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients' treatment response and their radio-sensitivity and chemo-sensitivity can be correlated with their survival outcome.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Patient derived organoids (10 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-27
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King's College London
Principal Investigators:
  • Anthony Kong (PRINCIPAL_INVESTIGATOR) - Clinical reader and honorary NHS consultant in clinical oncology
Contact Information
Study Contact:
Anthony Kong
0207 848 8302
Anthony.kong@kcl.ac.uk
Christiana Cattaneo
0207 848 8302
christiana.1.cattaneo@kcl.ac.uk
Anthony Kong
0207-848-8302
anthony.kong@kcl.ac.uk
Guy's and St. Thomas NHS Foundation Trust
Interventions
N/A
Study Locations (2 sites)
Guy's and St. Thomas NHS Foundation Trust, London, SE1 9RT United Kingdom
King's College Hospital NHS Foundation Trust, London, SE5 9RS United Kingdom
Eligibility Criteria
Inclusion Criteria: * Breast cancer patients with brain metastases who are suitable for surgical resection or Breast cancer patients with extra-cranial metastases undergoing surgical resection or biopsy * Age \> 18 years old Exclusion Criteria: * Patients unable to give informed consent e.g., mental disability or vulnerable adults
Conditions Cancer, Breast Cancer
Phase NA
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Whey protein (60 grams) — 60 grams of whey protein
  • Other: No protein — 0 grams of whey protein

Primary Outcomes

  • Determine changes in pounds of muscle and fat mass after each exercise regimen (Baseline and at program completion (within 4 weeks of exercise completion))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-18
Completion: 2028-06
Eligibility
Age: 20 Years – 89 Years
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Principal Investigators:
  • Colin Champ, MD, CSCS (PRINCIPAL_INVESTIGATOR) - AHN Radiation Oncology
Contact Information
Study Contact:
Clinical Trials Contact
412-330-6151
ctgov@ahn.org
Clinical Trials Contact
412-330-6151
ctgov@ahn.org
AHN Allegheny General Hospital
Clinical Trials Contact
4123306151
ctgov@ahn.org
AHN Allegheny General Hospital
Interventions
  • Dietary Supplement: Whey protein (60 grams) — 60 grams of whey protein
  • Other: No protein — 0 grams of whey protein
Study Locations (2 sites)
AHN Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States
AHN Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 20-89 years 2. Women prescribed exercise as a SOC 3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast 4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed. 5. Women with \> 3 months of resistance training experience under expert guidance by a CSCS 6. Must be able to read and understand English and consent for themselves. Exclusion Criteria: 1. Any current treatment with cytotoxic chemotherapy for breast cancer 2. Inability to safely engage in group sessions of resistance training as deemed by study PI 3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training 4. Beta blocker or GLP-1 inhibitor medications 5. Pregnant women 6. Males 7. Lactose intolerance 8. Cow's milk or whey protein allergy
Conditions Breast Cancer, Proton Therapy, Intensity...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this trial is to compare the toxicities and efficacy of intensity-modulated proton therapy (IMPT) and intensity-modulated radiation therapy (IMRT) for breast cancer patients indicated for radiotherapy including preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy. IMPT or IMRT will be administered to the whole breast, chest wall, and/or regional lymph nodes. A boost dose will be delivered in patients with high-risk area, at the discretion of the radiation oncologist. Eligible breast cancer patients will be followed for at least 5 years to assess acute and late radiation induced toxicities, loco-regional recurrence, overall survival, distant metastasis, and quality of life.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Radiation: Postoperative radiotherapy — Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed. A tumor bed boost will be provided to patients with high-risk factors following breast-conserving surgery, at the discretion of the radiation oncologist. The tumor bed boost regimen may consist of a sequential boost of 10-16 Gy (RBE) in 5-8 fractions, or 10-13.35 Gy (RBE) in 4-5 fractions or 10.4 Gy (RBE) in 2 fractions, or a simultaneous integrated boost of 48-49.5 Gy (RBE) in 15-16 fractions.
  • Radiation: Preoperative Radiotherapy — Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed.
  • Radiation: Definitive Radiotherapy — Radiotherapy was delivered using IMPT or IMRT. The target volume encompassed the ipsilateral whole breast and regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions was preferred. Alternatively, a conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions was permitted. Dose escalation was applied in high-risk areas, resulting in a total prescribed dose exceeding 66 Gy (RBE) when calculated as equivalent doses in 2-Gy fractions (EQD2), with an α/β ratio of 4.

Primary Outcomes

  • Complication Rate of ≥Grade 2 Acute Radiation-Induced Toxicity (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-01
Completion: 2029-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ruijin Hospital
Collaborators: Shandong Cancer Hospital and Institute, Sichuan Cancer Hospital and Research Institute, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center, Tongji Hospital
Principal Investigators:
  • Gang Cai, MD (PRINCIPAL_INVESTIGATOR) - Ruijin Hospital
  • Jia-Yi Chen, PhD, MD (STUDY_CHAIR) - Ruijin Hospital
Contact Information
Study Contact:
Gang Cai, MD
+86-021-64370045
cg11855@rjh.com.cn
Lu Cao, PhD, MD
+86-021-64370045
chenjiayi0188@aliyun.com
Gang Cai
+86-021-64370045
cg11855@rjh.com.cn
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Interventions
  • Radiation: Postoperative radiotherapy — Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed. A tumor bed boost will be provided to patients with high-risk factors following breast-conserving surgery, at the discretion of the radiation oncologist. The tumor bed boost regimen may consist of a sequential boost of 10-16 Gy (RBE) in 5-8 fractions, or 10-13.35 Gy (RBE) in 4-5 fractions or 10.4 Gy (RBE) in 2 fractions, or a simultaneous integrated boost of 48-49.5 Gy (RBE) in 15-16 fractions.
  • Radiation: Preoperative Radiotherapy — Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed.
  • Radiation: Definitive Radiotherapy — Radiotherapy was delivered using IMPT or IMRT. The target volume encompassed the ipsilateral whole breast and regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions was preferred. Alternatively, a conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions was permitted. Dose escalation was applied in high-risk areas, resulting in a total prescribed dose exceeding 66 Gy (RBE) when calculated as equivalent doses in 2-Gy fractions (EQD2), with an α/β ratio of 4.
Study Locations (1 sites)
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality 200025 China
Eligibility Criteria
Inclusion Criteria * Aged ≥18 years old * Karnofsky Performance Status (KPS) score ≥70 * Histologically confirmed breast cancer with indications for preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy as determined by the treating physician. * ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2), and Ki67 testing must be performed on the primary breast tumor. * Women of child-bearing potential must agree to use adequate contraception starting 1 month before study treatment and throughout the duration of study participation. * Ability to understand and willingness to participate in the research and sign the informed consent form. Exclusion Criteria * Pregnant or lactating women. * Severe non-neoplastic medical comorbidities that may interfere with treatment or study participation. * Active collagen vascular disease or other autoimmune disorders that could significantly increase the risk of radiation toxicity. * Patients with contraindications to undergoing IMPT or IMRT, such as severe claustrophobia that cannot be managed or inability to remain immobilized during treatment.
Conditions Lymphedema of Upper Limb
Phase Not Applicable
Enrollment 210
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

In this project, the investigators aim to investigate the imaging approaches for breast cancer-related secondary lymphedema. The clinical study aims to optimize the conventional MRI methods for mapping lymphedema and assess the post-surgical therapeutic effects in longitudinal follow-up studies. Additionally, a normal imaging database of lymphedema MRI images will be established for future reference. For pre-clinical animal study, investigators aim to develop and integrate two novel MRI methods, including free water elimination diffusion MRI and diffusion kurtosis MRI techniques. By integrating clinical and pre-clinical studies, the investigators aim to establish a precise imaging tool for evaluating the therapeutic effects of lymphedema for following translational applications.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Procedure: Diffusion magnetic resonance imaging — Free water elimination diffusion MRI and diffusion kurtosis MRI techniques

Primary Outcomes

  • change from baseline circumference of both arms at 3 months after lymphaticovenous anastomosis (baseline, 3 months after lymphaticovenous anastomosis)
  • change from baseline volume of both arms at 3 months after lymphaticovenous anastomosis (baseline, 3 months after lymphaticovenous anastomosis)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-10
Completion: 2026-12
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Collaborators: National Health Research Institutes, Taiwan
Principal Investigators:
  • Li-Wei Kuo, Ph.D. (PRINCIPAL_INVESTIGATOR) - National Health Research Institutes, Taiwan
Contact Information
Study Contact:
Yeefan Lee, MD
+886-972653172
yeefanlee@ntu.edu.tw
Yeefan Lee, MD
+886-2-2312-3456
yeefanlee@ntu.edu.tw
National Taiwan university hospital
Interventions
  • Procedure: Diffusion magnetic resonance imaging — Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
Study Locations (1 sites)
National Taiwan university hospital, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: * adults with breast cancer related lymphedema Exclusion Criteria: * children younger than 20 years old * pregnancy * patients who have absolute contraindications regarding MRI scanning: 1. The cardiac implantable electronic device (CIED) such as pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices. 2. Metallic intraocular foreign bodies. 3. Implantable neurostimulation systems 4. Cochlear implants/ear implant: bone-anchored hearing aid (BAHA) cochlear implant type can be scanned on a 1.5-tesla scanner only after the patient removes the battery. Cochlear implant wrapping scheduling must take place before the patient's MRI appointment. 5. Drug infusion pumps (insulin delivery, analgesic drugs, or chemotherapy pumps): If possible, the patient has to remove the device. 6. Catheters with metallic components (Swan-Ganz catheter) 7. Metallic fragments such as bullets, shotgun pellets, and metal shrapnel 8. Cerebral artery aneurysm clips 9. Magnetic dental implants 10. Tissue expander 11. Artificial limb 12. Hearing aid
Conditions Breast Cancer, Breast Reconstruction, Ba...
Phase Not Applicable
Enrollment 20000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this national registry-based study is to investigate the prevalence of reconstructive breast surgery and risk factors for surgical complications in women who have had weight loss surgery previously. The main questions it aims to answer are: 1. What is the perceived need for breast implants after weight loss surgery, described as the proportion who have breast implants, and what characteristics, in terms of demographics and surgical details, do the operated women have? 2. In women who have breast enlargement or breast enlargement combined with a lift, are there any differences between the women who have had weight loss surgery and other women regarding complications after the operation and characteristics of the surgery, for example skin incision and choice of implant (for example texture, shape, size)? 3. In women who have delayed breast reconstruction after breast cancer, that is have had their breast/s reconstructed in a separate operation, are there any differences between the women who have had weight loss surgery and other women regarding complications after the operation and characteristics of the surgery, for example in technique used (autologous versus implant-based, choice of implant, such as texture, shape and size), and timing of the surgery? Immediate breast reconstruction is defined as performed at the same time as the mastectomy, and delayed as an operation performed later in a separate operation. 4. In women who have immediate breast reconstruction after breast cancer?, that is have a breast reconstruction at the same time as the mastectomy, are there any differences between the women who have had weight loss surgery and other women regarding complications after the operation and characteristics of the surgery, for example in technique used (autologous versus implant-based, choice of implant, such as texture, shape and size), and timing of the surgery? Immediate breast reconstruction is defined as performed at the same time as the mastectomy, and delayed as an operation performed later in a separate operation. 5. In women who have risk reducing mastectomies, are there any differences between he women who have had weight loss surgery and other women regarding complications after the operation and characteristics of the surgery, for example in technique used (autologous versus implant-based, choice of implant, such as texture, shape and size), and timing of the surgery? Immediate breast reconstruction is defined as performed at the same time as the mastectomy, and delayed as an operation performed later in a separate operation. 6. Are there any identifiable risk factors for complications after breast reconstructive surgery, specific to the women who have had weight loss surgery and other women? Researchers will compare the patients to women who have the same type of reconstructive breast surgery but have not had bariatric surgery previously. The study will use prospectively collected data from seven registers: The…

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Procedure: Breast augmentation — Breast augmentation with an implant
  • Procedure: Breast reconstruction after mastectomy — Breast reconstruction after mastectomy

Primary Outcomes

  • Frequency of breast plastic surgery following bariatric surgery (10 years. The time frame is longer than the study duration, as it is based on already collected registry-based data.)
  • Demography (3 months)
  • Surgical details (3 months)
  • Complications and risk factors for complications (10 years)
  • Re-operations and risk factors for re-operations (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2028-12-31
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Principal Investigators:
  • Emma Hansson, professor, MD, PhD (PRINCIPAL_INVESTIGATOR) - Sahlgrenska University Hospital
Contact Information
Study Contact:
Emma Hansson, Professor, MD, Phd, MA
+46313421000
emma.em.hansson@vgregion.se
Emma Hansson, Professor, MD, PhD
+46313421000
emma.em.hansson@vgregion.se
Västra Götalandsregionen
Interventions
  • Procedure: Breast augmentation — Breast augmentation with an implant
  • Procedure: Breast reconstruction after mastectomy — Breast reconstruction after mastectomy
Study Locations (1 sites)
Västra Götalandsregionen, Gothenburg, Sweden
Eligibility Criteria
Inclusion Criteria: Inclusion in Soreg and thereafter inclusion in either BRIMP or NKBC Exclusion Criteria: \-
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 30
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will be performed after treatment completion. Patients with complete clinical response will proceed to surgery. Patients with clinical residual disease will complete neoadjuvant rescue with 4 cycles of doxorubicin/cyclophosphamide prior to surgery. If residual disease identified after surgery, adjuvant therapy to be determined by the treating oncologist (may include doxorubicin/cyclophosphamide/pembrolizumab, capecitabine etc).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Paclitaxel — chemotherapy
  • Drug: Carboplatin — chemotherapy
  • Drug: Pembrolizumab — immunotherapy
  • Drug: Doxorubicin — additional chemotherapy - neoadjuvant or adjuvant rescue
  • Drug: Cyclophosphamide — additional chemotherapy - adjuvant rescue
  • Drug: Olaparib — adjuvant rescue
  • Drug: Capecitabine — adjuvant rescue

Primary Outcomes

  • SULmax in relation to pCR (8 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-05-01
Completion: 2030-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Breast Cancer Research Foundation
Principal Investigators:
  • Cesar A Santa-Maria, MD (STUDY_CHAIR) - Johns Hopkins University
Contact Information
Study Contact:
Cesar A Santa-Maria, MD
410-614-0874
csantam2@jhmi.edu
Hopkins Breast Trials
410-614-1361
HopkinsBreastTrials@jhmi.edu
Hopkins Breast Trials
410-614-1361
HopkinsBreastTrials@jhmi.edu
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Interventions
  • Drug: Paclitaxel — chemotherapy
  • Drug: Carboplatin — chemotherapy
  • Drug: Pembrolizumab — immunotherapy
  • Drug: Doxorubicin — additional chemotherapy - neoadjuvant or adjuvant rescue
  • Drug: Cyclophosphamide — additional chemotherapy - adjuvant rescue
Study Locations (2 sites)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287 United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287 United States
Eligibility Criteria
Inclusion Criteria: 1. Stage II-III TNBC - estrogen receptor (ER) and progesterone receptor (PR) up to and including 10% is eligible 2. Age ≥ 18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 4. Eligible for standard chemo-immunotherapy as determined by treating physician, including consideration of: 1. Adequate marrow and organ function 2. Co-morbid conditions do not preclude the use of chemo-immunotherapy (such as uncontrolled autoimmune disease, or the use of immunosuppressive medications) 5. Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study Exclusion Criteria: 1. Patients unable to undergo PET or MRI 2. Evidence of metastatic disease or loco-regional recurrence (i.e. distant or chest wall recurrence) 3. Inflammatory breast cancer 4. Previous treatment with paclitaxel, carboplatin, or immune checkpoint inhibitors
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase NA
Enrollment 337
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, open-label, randomized controlled trial. It will prospectively compare outcomes between patients undergoing reverse-sequence endoscopic NSM (R-E-NSM) with direct-to-implant breast reconstruction (DIBR) with the "HUAXI Hole 1" versus without the "HUAXI Hole 1". The study aims to evaluate differences in operative efficiency, surgical safety, postoperative aesthetics, and oncological safety between the two groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: HUAXI hole 1 — A small incision of 2mm is made at the junction of the upper outer edge of the areola and the skin, through which the scalpel is placed to assist in the resection of breast glands in reverse-sequence nipple-sparing mastectomy and direct-to-implant breast reconstruction.

Primary Outcomes

  • Operative time (Immediate postoperative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-17
Completion: 2031-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 337 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Du Zhenggui
Collaborators: West China Tianfu Hospital, West China Fourth Hospital, Fourth People's Hospital of Sichuan Province, The First Affiliated Hospital of Zhengzhou University, The First Hospital of Jilin University, Shanxi Bethune Hospital, Chengdu Fifth People's Hospital, Suzhou Municipal Hospital, Taiyuan Central Hospital of Shanxi Medical University, The People's Hospital of DAZU ,Chongqing, Anyang City Tumor Hospital, Mianyang Hospital of Traditional Chinese Medicine, Sichuan Cancer Hospital and Research Institute, Deyang People's Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Guangzhou First People's Hospital, Fujian Medical University Union Hospital, Nanchang Third Hospital
Contact Information
Study Contact:
Zhenggui Du, MD
+86 13880768222
docduzg@163.com
Hui Dai, MD
+86 18075202377
daih108@163.com
Fangmeng Fu
+86 13365917923
ffm@fjmu.edu.cn
Fujian Medical University Union Hospital
Interventions
  • Procedure: HUAXI hole 1 — A small incision of 2mm is made at the junction of the upper outer edge of the areola and the skin, through which the scalpel is placed to assist in the resection of breast glands in reverse-sequence nipple-sparing mastectomy and direct-to-implant breast reconstruction.
Study Locations (20 sites)
Fujian Medical University Union Hospital, Fuzhou, Fujian 350000 China
Guangzhou First People's Hospital, Guangzhou, Guangdong 510000 China
Anyang City Tumor Hospital, Anyang, Henan 455000 China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000 China
The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410000 China
The Affiliated Hospital of lnner Mongolia Medical University, Hohhot, Inner Mongolia 010000 China
Suzhou Municipal Hospital, Suzhou, Jiangsu 215000 China
Nanchang People's Hospital, Nanchang, Jiangxi 330000 China
The First Hospital of Jilin University, Changchun, Jilin 130000 China
Shanxi Bethune Hospital, Taiyuan, Shanxi 030000 China
Eligibility Criteria
Inclusion criteria: * Female patients aged 18-70 years (inclusive18 and 70 years); * Patients eligible for unilateral or bilateral reverse-sequence endoscopic nipple-sparing mastectomy with immediate implant-based breast reconstruction, with concurrent contralateral endoscopic augmentation mammoplasty permitted; * Patients with preoperative pathological confirmation of non-specialized breast cancer (e.g., ductal carcinoma in situ, invasive ductal carcinoma, invasive lobular carcinoma) or eligibility for prophylactic mastectomy; * For non-specialized breast cancer patients, preoperative tumor size ≤5 cm (post-neoadjuvant chemotherapy if applicable), and no clinical or imaging evidence of invasion to the nipple, skin, subcutaneous fat, chest wall (referring to the bony thorax and intercostal muscles, excluding the pectoralis major and minor muscles) or distant metastasis preoperatively; * Patients volunteered to provide informed consent. Exclusion criteria: * History of open breast surgery within 1 year before this procedure (excluding minimally invasive vacuum-assisted biopsy); * Breast cancer diagnosed during pregnancy or lactation; * Subnipple-plane scarring with radiotherapy; * Metastatic breast cancer (M1); * Severe comorbidities precluding general anesthesia or surgery; * BMI ≥40 kg/m²; * HbA1c \>7.5%; * Immunodeficiency; * Active smoking with ≥20 cigarettes per day * Patients with concurrent participation in conflicting clinical trials.
Conditions Rare Disorders, Undiagnosed Disorders, D...
Phase Not Applicable
Enrollment 20000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts. Through partnerships with patient advocacy organizations and researchers worldwide, CoRDS helps connect rare disease communities with research opportunities while advancing knowledge across more than 7,000 rare diseases. Participation is free of charge.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases. (100 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2010-07
Completion: 2100-12
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sanford Health
Collaborators: National Ataxia Foundation, International WAGR Syndrome Association, 4p- Support Group, ML4 Foundation, Cornelia de Lange Syndrome Foundation, Stickler Involved People, Kawasaki Disease Foundation, Klippel-Feil Syndrome Alliance, Klippel-Feil Syndrome Freedom, Hyperacusis Research Limited, Hypersomnia Foundation, Kabuki Syndrome Network, Kleine-Levin Syndrome Foundation, Leiomyosarcoma Direct Research Foundation, Marinesco-Sjogren Syndrome Support Group - NORD, Mucolipidosis Type IV (ML4) Foundation, People with Narcolepsy 4 People with Narcolepsy (PWN4PWN), Soft Bones Incorporated, American Multiple Endocrine Neoplasia Support, Atypical Hemolytic Uremic Syndrome Foundation, All Things Kabuki, Wiedemann-Steiner Syndrome Foundation, Breast Implant Victim Advocates, PROS Foundation, American Behcet's Disease Association, Alstrom United Kingdom, Athymia, Curing Retinal Blindness Foundation, HSAN1E Society, 1p36 Deletion Support and Awareness, The Alagille Syndrome Alliance, Autoinflammatory Alliance, Beyond Batten Disease Foundation, Bohring-Opitz Syndrome Foundation, INC, Cockayne Syndrome Network (Share and Care), CRMO Foundation, Cure VCP Disease,INC, FOD Support, Cystinosis Research Foundation, Global DARE Foundation, Hypnic Jerk-Sleep Myoclonus Support Group, Jansen's Foundation, KCNMA1 Channelopathy International Advocacy Foundation, Kawasaki Disease Foundation Australia, Life with LEMS Foundation, Lowe Syndrome Association, The Malan Syndrome Foundation, Maple Syrup Urine Disease Family Support Group, International Association for Muscle Glycogen Storage Disease (IamGSD), Myhre Syndrome Foundation, DNM1 Families, Nicolaides Baraitser Syndrome (NCBRS) Worldwide Foundation, The PBCers Organization, Pitt Hopkins Research Foundation, Recurrent Meningitis Association, Recurrent Respiratory Papillomatosis Foundation, Remember the Girls, Smith-Kingsmore Syndrome Foundation, SPG Research Foundation, Team Telomere, Transient Global Amnesia Project, The Charlotte & Gwenyth Gray Foundation, The Cute Syndrome Foundation, The Maddi Foundation, White Sutton Syndrome Foundation, Zmynd11 Gene Disorder, Cauda Equina Foundation, Inc, Tango2 Research Foundation, Noah's Hope - Hope4Bridget Foundation, Project Sebastian, SMC1A DEE Foundation, International Foundation for Gastrointestinal Disorders, Endosalpingiosis Foundation, Inc, International Sacral Agenesis/Caudal Regression Association (ISACRA), Scheuermann's Disease Fund, Batten Disease Support and Research Association, Kennedy's Disease Association, Cure Mito Foundation, Warburg Micro Research Foundation, Cure Mucolipidosis, Riaan Research Initiative, CureARS A NJ Nonprofit Corporation, CACNA1H Alliance, IMBS Alliance, SHINE-Syndrome Foundaion, Non- Ketotic Hyperglycinemia (NKH) Crusaders, Hypertrophic Olivary Degeneration Association (HODA), National Organization for Disorders of the Corpus Callosum (NODCC), Team4Travis, Taylor's Tale Foundation, Lambert Eaton (LEMS) Family Association, BARE Inc, STAG1 Gene Foundation, Coffin Lowry Syndrome Foundation, BLFS Incorporate, Aniridia North America, Cure Blau Syndrome Foundation, ARG1D Foundation, CURE HSPB8 Myopathy, International Society of Mannosidosis and Related Disorders, TBX4Life, Cure DHDDS, MANDKind Foundation, Krishnan Family Foundation, SPATA Foundation, Acrodysostosis Support and Research, ACTA2 Alliance, ANA-Aniridia North America, CRELD1 Warriors, GNB1 Advocacy Group, Hope for PDCD Foundation, ISMRD - Beta Mannosidosis, KBG Syndrome Association, The LCC Foundation, MLD Foundation, MSA United Research Consortium, Moyamoya Foundation, OPMD Association, SKDEAS Foundation, The Foundation for Casey's Cure, TUBB3 Foundation, WWOX Foundation
Contact Information
Study Contact:
CoRDS Team
1-877-658-9192
cords@sanfordhealth.org
CoRDS Team
877-658-9192
cords@sanfordhealth.org
Sanford Health
Chun Hung Chan, PhD
Sanford Health
Interventions
N/A
Study Locations (1 sites)
Sanford Health, Sioux Falls, South Dakota 57104 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of a rare disease, a disease of unknown prevalence, undiagnosed or an unaffected carrier of a rare/uncommon disease Exclusion Criteria: * Diagnosis of a disease which is not rare